On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NTRA, Financial), sold 1,238 shares of the company. The transaction was filed on the same day with the SEC.
Natera Inc specializes in genetic testing and diagnostics with a focus on women’s health, oncology, and organ health. The company aims to provide precise and actionable results to guide health decisions.
Over the past year, the insider has sold a total of 90,830 shares and has not made any purchases. This recent sale is part of a broader trend at Natera Inc, where there have been 83 insider sells and no insider buys over the past year.
Shares of Natera Inc were priced at $93.14 on the day of the sale, bringing the market cap of the company to approximately $11.51 billion.
According to the GF Value, the intrinsic value of Natera Inc is estimated at $65.60 per share, making the stock significantly overvalued with a price-to-GF-Value ratio of 1.42.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
